Key facts
- Biond Biologics and Guangzhou-Israel Biotechnology Fund (GIBF) closed an $8 million investment.
- The companies will collaborate to advance oncology programs.
- The collaboration focuses on programs in China.
This investment and collaboration between Biond Biologics and GIBF signifies a strategic move to leverage Biond's oncology programs within the Chinese market. GIBF's involvement suggests a focus on bridging international biotechnology innovation with Chinese market opportunities.